Behind the headline of universal healthcare resulting from the recent Obama administration reforms, lies the simultaneous change to the regulation of biologic drugs imposed by the new legislation. The change concerns the data exclusivity period and process for follow-on biologic approval by the FDA. The Approval Pathway For Biosimilar Biological Products, provides clarity on an […]
